Inspire Therapy for Sleep Apnea

Hypoglossal nerve stimulation is the broader therapy class: implanted devices that treat obstructive sleep apnea by stimulating the hypoglossal nerve so the tongue moves forward and the upper airway stays more open during sleep.

Inspire is one specific system within that class, the first to receive FDA approval for this use and the one most commonly discussed by name. It is a distinct, well-defined product, not another word for the whole category, and other systems built on the same general therapy class exist as well.

That distinction matters for patients doing their own research. General information about how hypoglossal nerve stimulation works as a therapy class, its overall candidacy concept, and its general limitations applies broadly to Inspire, but the specific pathway, from implantation to activation to daily use, described below reflects this particular FDA-approved system.

The mechanism, briefly: a sensing lead placed near the ribs detects the pattern of breathing, and a small pulse generator implanted under the skin in the upper chest uses that information to deliver mild electrical stimulation to a branch of the hypoglossal nerve in the neck, timed to specific points in the breathing cycle.

That stimulation causes the tongue and nearby tissue to move slightly forward, reducing the tissue collapse at the back of the throat that causes obstructive sleep apnea.

Unlike CPAP, which mechanically holds the airway open with continuous air pressure delivered through a mask, Inspire works by prompting the airway’s own muscles to hold themselves open.

Inspire is placed during an outpatient surgical procedure performed under general anesthesia, typically lasting a few hours. A surgeon positions the small stimulation lead near the hypoglossal nerve in the neck, the sensing lead near the ribs to detect breathing effort, and the pulse generator under the skin in the upper chest, similar in size and placement concept to a cardiac pacemaker.

Most patients go home the same day and resume normal activities within one to two weeks, with some restrictions on neck movement and strenuous activity during initial healing.

Getting Inspire to an effective and comfortable setting is rarely a one-visit process. Stimulation levels are typically increased gradually over a series of follow-up visits as a patient adjusts to the sensation, with the clinical team balancing effectiveness against tolerability.

Many programs use a follow-up in-lab sleep study during this period, conceptually similar to a CPAP titration study, to directly measure how well a given setting is controlling apnea events rather than relying on symptoms alone. Settings can continue to be refined at later visits if needed.

For appropriately selected patients, published research and clinical experience with Inspire have shown meaningful reductions in sleep apnea severity and improvement in symptoms such as daytime sleepiness. That said, individual results vary meaningfully, some patients see a larger benefit than others, and Inspire does not eliminate obstructive sleep apnea for everyone who receives it.

It is also not without downsides: as an implanted device placed through surgery, it carries general surgical and anesthesia risks along with the possibility of tongue discomfort or an unfamiliar stimulation sensation, especially early in the adjustment period.

For these reasons, Inspire is generally considered after CPAP and other non-surgical approaches have been genuinely tried, rather than as a routine starting point for a new sleep apnea diagnosis.